# Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

> **NCT02535247** · PHASE1,PHASE2 · TERMINATED · sponsor: **Fox Chase Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Lymphoma, T-Cell, Peripheral

## Interventions

- **DRUG:** MK-3475
- **DRUG:** Copanlisib

## Key facts

- **NCT ID:** NCT02535247
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01-05
- **Primary completion:** 2020-02-25
- **Final completion:** 2020-02-25
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Merck no longer providing drug for study
- **Last updated:** 2022-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02535247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02535247, "Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02535247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*